Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxcarbazepine - Novartis

Next Previous
X
Search
Drug Profile

Oxcarbazepine - Novartis

Alternative Names: GP 47680; KIN-493; NPC 04; Oxacarbazepine; TRI 476; Trileptal

Latest Information Update: 25 Sep 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Queen Mary University of London
  • Class Antiepileptic drugs; Dibenzazepines; Mood stabilisers; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Phase II Multiple sclerosis
  • Discontinued Bipolar disorders; Diabetic neuropathies; Neurological disorders

Most Recent Events

  • 01 Jul 2019 Oxcarbazepine is not yet available for Epilepsy in Japan (PO)
  • 31 Jan 2018 Queen Mary University of London completes a phase II trial in Multiple sclerosis in United Kingdom (PO) (NCT02104661)
  • 04 Jul 2016 Registered for Epilepsy in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top